TriangleMosunetuzumab (NCT05389293)
Mosunetuzumab trial for Follicular Lymphoma (NCT05389293). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated grade 1–3A follicular lymphoma, selected stage II–IV disease, and a need for systemic treatment. Patients must be fit for chemoimmunotherapy.
The idea: mosunetuzumab links lymphoma cells to T cells. Another group adds zanubrutinib, which blocks BTK survival signaling. Mosunetuzumab is injected under the skin every three weeks after initial step-up doses. Complete response stops it after eight cycles; zanubrutinib continues for twelve months in the combination group.
This phase 2 study plans 152 patients. Lorenzo Falchi leads at Memorial Sloan Kettering; nine US locations are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.